

015
MAY 2 1 2002
PATENT & TRADEMARK

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

MARK B. WILSON
PARTNER

INTERNET ADDRESS:
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: 512/536-3035


1644
HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

COPY OF PAPERS
ORIGINALLY FILED

5/21/02

May 8, 2002

FILE: EPCL:001USC2

CERTIFICATE OF MAILING	
37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
May 8, 2002	
Date	Mark B. Wilson

RECEIVED
MAY 23 2002
TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231

RE: *U.S. Patent Application No. 09/989,902 entitled "THERAPEUTIC SYSTEMS USING ENZYMATICALLY-ACTIVE COMPOUNDS CAPABLE OF RELEASING CYANIDE FROM A CYANOGENIC PRODRUG HAVING A PORTION ABLE TO TARGET A CELL" - Agamemnon A. Epenetos and Gail Rowlinson-Busza. (Client Reference: ANTT/P13199U1)*


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10111745/MBW.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Mark B. Wilson
Reg. No. 37,259

MBW/cmb

Encl: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Agamemnon A. Epenetos
Gail Rowlinson-Busza

Serial No.: 09/989,902

Filed: November 19, 2001

For: THERAPEUTIC SYSTEMS USING
ENZYMATICALLY-ACTIVE
COMPOUNDS CAPABLE OF
RELEASING CYANIDE FROM A
CYANOGENIC PRODRUG HAVING A
PORTION ABLE TO TARGET A CELL


Group Art Unit: 1644

Examiner: Unknown

Atty. Dkt. No.: EPCL:001USC2/MBW

RECEIVED
MAY 23 2002
TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:	
May 8, 2002	
Date	Mark B. Wilson

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10111745/MBW.

This application is a continuation application of Serial No. 08/291,332, filed August 17, 1994, which is a continuation of Serial No. 07/910,303 filed September 23, 1992, and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial Nos. 08/291,332 and 07/910,303.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 8, 2002



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
EPCL:001USC2/MBWSerial No.
09/989,902Applicant
Agamemnon A. Epenetos
Gail Rowlinson-BuszaFiling Date:
November 19, 2001Group:
1644

MAY 23 2002

RECEIVED

TECH CENTER 1600/2900

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	CA 1,216,791	1/20/87	Canada			
	B1	EP 0142905	5/29/85	Europe			
	B1	EP 0302473	8-3-88	Europe			
	B1	WO 87/03205	6-4-87	PCT			
	B1	WO 88/07378	10-6-88	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Ardenne <i>et al.</i> , "Tumour hyperacidulation through intravenous glucose infusion enhanced by amygdalin and beta-glucosidase application," <i>Arch Geschwulstforsch.</i> , (abstract) 45(2): 135-145, 1975.
	C2	Bagshawe <i>et al.</i> , "Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial," <i>Tumor Targeting</i> , 1:17-29, 1995.
	C3	Bagshawe <i>et al.</i> , "A cytotoxic agent can be generated selectively at cancer sites," <i>Br. J. Cancer</i> , 58:700-703, 1988.
	C4	Bagshawe, K. D., "Antibody directed enzymes revive anti-cancer prodrugs concept," <i>Br. J. Cancer</i> , 56:531-531, 1987.
	C5	Bamias <i>et al.</i> , "Intravesical administration of radiolabeled antitumor monoclonal antibody in bladder carcinoma," <i>Cancer Res.</i> 51:724-728, 1991.
	C6	Biotechnology Business News, pp 1 & 11, 1991.

25147165.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

COPY OF PAPERS
ORIGINALLY FILED



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

EPCL:001USC2/MBW

Serial No.

09/989,902

Applicant

Agamemnon A. Epenetos

Gail Rowlinson-Busza

Filing Date:

November 19, 2001

Group:

1644

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Butschak <i>et al.</i> , "Cleavage of alpha-L-arabinofuranoside, beta-D-glucopyranoside and beta-cellobioside of 4-nitrophenol by enzymes of various fungi - A contribution to increase the selectivity of tumor therapy," (abstract), <i>Z. Allg. Mikrobiol.</i> , 16:507-519, 1976.
	C8	Campbell, "Monoclonal antibody technology," Elsevier Press, pp.151-165, 1984.
	C9	Carlet <i>et al.</i> , "Protease-activated 'prodrugs' for cancer chemotherapy," <i>Proc. Natl. Acad. Sci. USA</i> , 77:2224-2228, 1980.
	C10	Chahinian <i>et al.</i> , "Usefulness of the nude mouse model in mesothelioma based on a direct patient-Xenograft comparison," <i>Cancer</i> , 68:558-560, 1991.
	C11	Chopin <i>et al.</i> , "Detection of transitional cell carcinoma in bladder by intravesical injection of monoclonal antibodies," <i>Urol. Res.</i> , (abstract) 14(3):145-148, 1986.
	C12	Connors, "Antitumour drugs with latent activity," <i>Biochemie</i> , 60:980-987, 1978.
	C13	Cox and Farmer, "Towards selectivity? Approaches to the design of new anti-tumour agents-I," <i>Cancer Treatment Rev.</i> , 4:47-63, 1977.
	C14	Curti, "Physical barriers to drug delivery in tumors," <i>Critical Reviews in Oncology/Hematology</i> , 14:29-39, 1993.
	C15	Dermer, "Another anniversary for the war on cancer," <i>Bio/Technology</i> , 12:320, 1994.
	C16	Edington, "How sweet it is: selectin-meidating drugs," <i>Bio/Technology</i> , 10:383-389, 1992.
	C17	English translation of Von Ardenne & Reitnauer, pp.1-16.
	C18	Foon, "Biological response modifiers: The new immunotherapy," <i>Cancer Res.</i> , 49:1621-1639, 1989.
	C19	Ghanem <i>et al.</i> , "Human melanoma targeting with α -MSH-melphanlan conjugate," <i>Melanoma Res.</i> , 1:105-114, 1991.
	C20	Ghose and Blair, "Antibody-linked cytotoxic agents in the treatment of cancer: Current status and future prospects," <i>J. Natl. Cancer Inst.</i> , 67:657-676, 1978.
	C21	Gregoriadis, "Targeting of Drugs," <i>Nature</i> , 265:407-411, 1977.
	C22	Harris <i>et al.</i> , "Therapeutic antibodies - the coming of age," <i>TIBTECH</i> , 11:42-44, 1993.

25147165.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.

EPCL:001USC2/MBW

Serial No.

09/989,902

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Agamemnon A. Epenetos

Gail Rowlinson-Busza

RECEIVED

Filing Date:

November 19, 2001

Group:

1644

MAY 23 2002

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	Hird and Epenetos, "Immunotherapy with monoclonal antibodies," Chapter 17 In: <i>Genes and Cancer</i> , Carney <i>et al.</i> (eds.), John Wiley and Sons, 183-189, 1990.
	C24	Hird <i>et al.</i> , "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody," <i>Br. J. Cancer</i> , 68:403-406, 1993.
	C25	Jain, "Barriers to drug delivery in solid tumors," <i>Sci. America</i> , 271:58-65, 1994.
	C26	Kerr <i>et al.</i> , "Antibody penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxycetamide," <i>Cancer Immunol. Immunother</i> , 31:202-206, 1990.
	C27	Knowles <i>et al.</i> , "In vitro antibody-enzyme conjugates with specific bactericidal activity," <i>J. Clin. Invest.</i> , 52:1443-1452, 1973.
	C28	Kuefner <i>et al.</i> , "Carboxypeptidase-mediated release of methotrexate from methoxytexas α -peptides," <i>Biochemistry</i> , 28:2288-2297, 1989.
	C29	Lakow and Basch, "Positive immunoselection using antibody-enzyme complexes," <i>J. Immunol. Meth.</i> , 44:135-151, 1981.
	C30	Lal <i>et al.</i> , "Selective elimination of lymphocyte subpopulations by monoclonal antibody-enzyme conjugates," <i>J. Imm. Methods</i> , 79:307-318, 1985.
	C31	Liebert <i>et al.</i> , "The monoclonal antibody BQ16 identifies the $\alpha 6 \beta 4$ integrin on bladder cancer," <i>Hybridoma</i> , 12(1):67-80, 1993.
	C32	Lyle and Parker, "New approaches to immunosuppression," <i>Fed. Proc.</i> , 33:1889-1893, 1974.
	C33	Moertel <i>et al.</i> , "A clinical trial of amygdalin 9laetrole) in the treatment of human cancer," <i>N. Engl. J. Med.</i> , 306:201-206, 1982.
	C34	Osband and Ross, "Problems in the investigational study and clinical use of cancer immunotherapy," <i>Imm. Today</i> , 11:103-105, 1990.
	C35	Parker <i>et al.</i> , "Enzymatic activation and trapping of luminol-substituted peptides and proteins. A possible means of amplifying the cytotoxicity of the anti-tumor antibodies," <i>Proc. Natl. Acad. Sci. USA</i> , 72:338-342, 1975.
	C36	Parker <i>et al.</i> , "The immunologic therapy of cancer," <i>Pharmacology and the Future of Man</i> , 5:411-419, 1973.


25147165.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

Atty. Docket No.
EPCL:001USC2/MBWSerial No.
09/989,902List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Agamemnon A. Epenetos
Gail Rowlinson-BuszaFiling Date:
November 19, 2001Group:
1644

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C37	Parker <i>et al.</i> , "The immunotherapy of cancer," <i>Pharmacol. Rev.</i> , 25:325-342, 1973.
	C38	Parker, "Immunologically directed cell destruction," <i>Immunologic Intervention</i> , 176-206, 1971.
	C39	Paulus, <i>Int. Mitt.</i> , 78, 118-132, 1985.
	C40	Philpott <i>et al.</i> , "Affinity cytotoxicity of tumour cells with antibody-glucose oxidase conjugates, peroxidase and arspenamine," <i>Cancer Res.</i> , 34: 2159-2164, 1974.
	C41	Philpott <i>et al.</i> , "Selective binding and cytotoxicity of rat basophilic leukemia cells (RBL-1) with immunoglobulin E-biotin and avidin-glucose oxidase conjugates," <i>J. Immunol.</i> , 125:1201-1209, 1980.
	C42	Philpott and Parker, "Affinity cell killing with an antibody-alcohol dehydrogenase conjugate and allyl alcohol," <i>Proceedings of AACR and ASCO</i> , 81:21, 1975.
	C43	Philpott <i>et al.</i> , "Affinity cytotoxicity with an alcohol dehydrogenase antibody conjugate and allyl alcohol," <i>Cancer Res.</i> , 39:2084-2089, 1979.
	C44	Philpott <i>et al.</i> , "Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate," <i>J. Immunol.</i> , 111:921-929, 1973.
	C45	Poulton, "Cyanogenesis in plants," <i>Plant Physiol.</i> , 94:401-405, 1990.
	C46	Poulton, "Localization and catabolism of cyanogenic glycosides," <i>Ciba Foundation Symposium 140</i> , pp.67-91, 1988.
	C47	Poupon <i>et al.</i> , "Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates," <i>J. Natl Cancer Institute</i> , 85(24):2023-2029, 1993.
	C48	Riethmuller <i>et al.</i> , "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <i>Lancet</i> , 343:1177-1183, 1994.
	C49	Rowlinson-Busza <i>et al.</i> , "Antibody guided enzymes activation of amygdalin," <i>Eur J. Cancer</i> , 26:1020,1190
	C50	Rowlinson-Busza <i>et al.</i> , "Cytotoxicity following specific activation of amygdalin," Chapter 18, In: <i>Monoclonal Antibodies: Applications in Clinical Oncology</i> , Epenetos (ed.), Chapman and Hall, 179-183, 1991.
	C51	Senter <i>et al.</i> , "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <i>Proc. Natl. Acad. Sci., USA</i> , 85:4842-4846, 1988.


25147165.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.
EPCL:001USC2/MBWSerial No.
09/989,902

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Agamemnon A. Epenetos
Gail Rowlinson-BuszaFiling Date:
November 19, 2001Group:
1644

MAY 23 2002

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

RECEIVED

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C52	Senter <i>et al.</i> , "Enchantment of the in vitro and in vivo antitumour activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphates conjugates," <i>Cancer Res.</i> , 49:5789-5792, 1989.
	C53	Senter, "Activation of prodrugs by antibody-enzymes conjugates: a new approach to cancer therapy," <i>FASEB J.</i> , 4:188-193, 1990.
	C54	Senter, "The present and future role of monoclonal antibodies in the management of cancer," <i>Front. Radial. Ther. Oncol.</i> , 24:133-141, 1990.
	C55	Shearer <i>et al.</i> , "Cytotoxicity with antibody-glucose oxidase conjugates specific for human colonic cancer and carcinoembryonic antigen," <i>Int. J. Cancer</i> , 14:539-547, 1974.
	C56	Simpson, <i>Genetic Engineering News</i> , 1:7, 1991.
	C57	Spurr <i>et al.</i> , "Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody auai." <i>Int. J. Cancer</i> , 38:631-636, 1986.
	C58	Sullivan <i>et al.</i> , "Specific killing of parasites by antibody-enzyme conjugates," <i>Res. Comm. Chem. Pathol.</i> , 6:709-717, 1973.
	C59	Thorpe <i>et al.</i> , "Comparison of two anti-Thy 1.1-Abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants," <i>JNCI</i> , 79(5):1101-1112, 1987.
	C60	Waldmann <i>et al.</i> , "Monoclonal antibodies in diagnosis and therapy," <i>Science</i> , 252:1657-1662, 1991.

COPY OF PAPERS
ORIGINALLY FILED

25147165.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)